Tag
Anti-PD-1 antibody exacerbates pressure overload-induced heart failure by promoting CXCR3+ CD8+ T cell infiltration, which impairs cardiomyocyte mitochondrial function via granzyme B and perforin. This study identifies a novel immunopathoge
Participation in the GWTG-HF program modestly improves guideline-directed medical therapy intensity and reduces short- and long-term mortality in patients hospitalized for heart failure with reduced ejection fraction.
This review synthesizes evidence linking short-term exposure to cold and heat extremes with increased heart failure hospitalizations, highlighting mechanistic biomarker studies and telemonitoring findings that elucidate temperature-driven H
The HELIOS-B trial demonstrates that vutrisiran significantly reduces mortality and cardiovascular events in ATTR-CM patients, with its efficacy unaffected by concurrent use of tafamidis or heart failure medications, supporting its broad th
A nurse-led, mobile health-supported collaborative care intervention significantly increased days alive and out of hospital and reduced mortality among Indian patients with heart failure with reduced ejection fraction over 2 years.
This review synthesizes current evidence on hemoglobin thresholds in heart failure, highlighting that optimal prognosis is associated with hemoglobin levels higher than WHO anemia cutoffs, with clinical implications for management and iron
This study reveals distinct sex differences in skeletal muscle inflammation and dysfunction in patients with HFrEF, highlighting divergent immune cell profiles linked to muscle mass and strength variations in men versus women, advancing und
A Swedish cohort study reveals increased adoption and high adherence to quadruple pharmacotherapy in HFrEF, associating treatment persistence with better clinical outcomes and highlighting areas for improved dosing and continuation.
This study demonstrates the lack of mechanistic specificity of clinical capillary leak indices in heart failure patients, underscoring their limitations as universal markers of endothelial permeability beyond acute inflammatory states.
A clear, global update standardizing heart failure terminology, phenotypes, causes, and trajectories to improve prevention, diagnosis, treatment, and global surveillance.
This article reviews improvements in heart failure management and outcomes in Japan between 2013 and 2019-21, highlighting increased guideline-based therapy use and enhanced post-discharge care leading to reduced mortality and readmission r
The TARTAN-HF trial demonstrated that targeted natriuretic peptide screening in high-risk diabetic patients uncovers a high prevalence of undiagnosed heart failure, mainly HFpEF, enabling earlier treatment initiation and improved clinical c
The RELIEVE-HF trial reveals distinct predictors of outcomes after interatrial shunt implantation in HFrEF and HFpEF, enabling personalized risk modeling to identify patients likely to benefit from this therapy.
This study reveals a high heart failure risk within 5 years of diabetes diagnosis, highlighting insulin resistance and reduced kidney function as independent predictors beyond conventional risk factors.
This meta-analysis of four placebo-controlled trials reveals no significant difference in the efficacy and safety of mineralocorticoid receptor antagonists between Black and non-Black patients with heart failure, regardless of heart failure
This review synthesizes contemporary evidence on the survival impact of adding defibrillators to CRT in nonischemic cardiomyopathy, highlighting heterogeneous results including the DECIDE-CRT study and underscoring the need for personalized
A large Chinese cohort study reveals a U-shaped association between left ventricular end-diastolic diameter and mortality in heart failure, highlighting both small and large ventricular sizes as independent risk factors.
Acoramidis demonstrates substantial benefits in heart failure-related health status among ATTR-CM patients, significantly improving patient-reported outcomes and supporting its role in modifying disease trajectory.
In a randomized trial among Navajo patients with heart failure, an 8-week culturally tailored meal program reduced all-cause hospitalization or ED visits by 28% compared with usual dietary advice, with improvements in quality of life and food security.
This review synthesizes contemporary evidence on initiation, adherence, and persistence of guideline-directed medical therapy after heart failure hospitalization, highlighting critical gaps and strategies to improve long-term patient outcom
